Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DLV0Z8
|
|||
Drug Name |
REMD 477
|
|||
Synonyms |
Volagidemab
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Type-1 diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 1/2 | [2] | ||
Type-2 diabetes [ICD-11: 5A11] | Phase 1/2 | [3] | ||
Company |
REMD Biotherapeutics
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon receptor (GCGR) | Target Info | Antagonist | [4] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Glucagon signaling pathway | ||||
Reactome | Glucagon signaling in metabolic regulation | |||
G alpha (q) signalling events | ||||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03117998) Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus. U.S. National Institutes of Health. | |||
REF 2 | ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||
REF 3 | ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||
REF 4 | Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.